Lercanidipino Aurovitas Spain (Lercanidipine Hydrochloride)

• Lercanidipine Hydrochloride is a calcium channel blocker used to manage elevated blood pressure within the cardiovascular disease pathway.
• Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

• Lercanidipine Hydrochloride selectively inhibits L-type calcium channels in vascular smooth muscle cells, preventing calcium influx. This leads to relaxation of arterial smooth muscle, vasodilation, and a reduction in peripheral vascular resistance, thereby lowering systemic blood pressure.

Lercanidipine Hydrochloride may cause a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: especially upon standing.
• Tachycardia: increased heart rate.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Angioedema: swelling of face, lips, tongue, or throat.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Myocardial infarction: rare occurrence of heart attack.
• Cardiac arrhythmia: irregular heart rhythm.

• Before initiating therapy, clinicians should consider several safety measures.
• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess liver function: evaluate hepatic enzymes periodically.
• Caution in elderly patients: start with lower doses due to altered pharmacokinetics.
• Avoid abrupt discontinuation: taper to prevent rebound hypertension.
• Review concomitant antihypertensives: adjust doses to avoid additive hypotension.
• Store at room temperature: keep in the original pack, protect from moisture.

Lercanidipine Hydrochloride can interact with various medicines, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Concurrent use with other calcium channel blockers: risk of excessive vasodilation.
• Combination with potent antihypertensives (e.g., ACE inhibitors, ARBs) leading to severe hypotension.

Moderate Interactions (Monitor Closely)

• Grapefruit juice: can modestly raise drug concentrations.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential impact on renal function and blood pressure control.